Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clamikalant (Aventis).

S T O'Rourke1

  • 1Department of Pharmaceutical Sciences, North Dakota State University, Fargo, ND 58105-5055, USA. orourke@badlands.nodak.edu

Idrugs : the Investigational Drugs Journal
|July 28, 2005
PubMed
Summary

Clamikalant, a novel ATP-dependent potassium channel (KATP) blocker, shows promise for treating cardiac arrhythmia. It effectively prevented ventricular fibrillation in dogs without adverse hemodynamic or glycemic effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic blockade of class I PI3-kinase attenuates Ang II-induced cardiac hypertrophy and autophagic alteration.

European review for medical and pharmacological sciences·2015
Same author

Effect of maternal nutrient restriction and melatonin supplementation from mid to late gestation on vascular reactivity of maternal and fetal placental arteries.

Placenta·2014
Same author

2011 and 2012 Early Careers Achievement Awards: Placental programming: how the maternal environment can impact placental function.

Journal of animal science·2013
Same author

Melatonin potentiates contractile responses to serotonin in isolated porcine coronary arteries.

American journal of physiology. Heart and circulatory physiology·2000
Same author

Dexfenfluramine-induced contraction of human and rat isolated pulmonary arteries.

European journal of pharmacology·2000
Same author

Steroid effects at the membrane level on oxytocin systems.

Annals of the New York Academy of Sciences·1997

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Ion Channel Research

Background:

  • Cardiac arrhythmia poses a significant health risk.
  • ATP-dependent potassium channels (KATP) play a crucial role in cardiac function.
  • Developing targeted therapies for cardiac arrhythmia is a priority.

Purpose of the Study:

  • To evaluate the efficacy and safety of Clamikalant, a cardioselective KATP channel blocker.
  • To assess the anti-arrhythmic effects of Clamikalant and its sodium salt (HMR-1098).
  • To investigate the impact of Clamikalant on hemodynamic parameters and blood glucose levels.

Main Methods:

  • Preclinical studies involving canine models of ventricular fibrillation.
  • Assessment of electrophysiological properties in isolated rabbit hearts.
  • Evaluation of hemodynamic effects and blood glucose levels post-administration.

Main Results:

  • Clamikalant prevented ischemia-induced reductions in refractory period in dogs with ventricular fibrillation.
  • No significant hemodynamic alterations or changes in blood glucose levels were observed.
  • HMR-1883 demonstrated an anti-arrhythmic effect in isolated rabbit hearts without interfering with post-ischemic hyperemia.

Conclusions:

  • Clamikalant exhibits potent anti-arrhythmic properties with a favorable safety profile.
  • The drug's cardioselectivity and lack of significant side effects suggest therapeutic potential for cardiac arrhythmia.
  • Further clinical development, including phase II trials for HMR-1098, is warranted.

Related Experiment Videos